Pfizer has completed patient enrollment in a Phase II study involving administration of Athersys Inc.‘s MultiStem cell therapy to ulcerative colitis patients. The trial, part of a 2009 collaboration agreement between Athersys and Pfizer, is a randomized, double-blind, placebo-controlled, multi-center clinical trial evaluating the safety and efficacy of MultiStem therapy in subjects with moderate to severe ulcerative colitis. Initial results from the study are expected to be disclosed by 2Q...